About amylyx pharmaceuticals inc - AMLX
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
AMLX At a Glance
Amylyx Pharmaceuticals, Inc.
43 Thorndike Street
Cambridge, Massachusetts 02141
| Phone | 1-617-682-0917 | Revenue | 87.37M | |
| Industry | Pharmaceuticals: Major | Net Income | -301,743,000.00 | |
| Sector | Health Technology | Employees | 123 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
AMLX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.948 |
| Price to Book Ratio | 1.574 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.326 |
| Enterprise Value to Sales | 0.951 |
| Total Debt to Enterprise Value | 0.024 |
AMLX Efficiency
| Revenue/Employee | 710,333.333 |
| Income Per Employee | -2,453,195.122 |
| Receivables Turnover | 159.728 |
| Total Asset Turnover | 0.246 |
AMLX Liquidity
| Current Ratio | 6.669 |
| Quick Ratio | 6.669 |
| Cash Ratio | 6.214 |
AMLX Profitability
| Gross Margin | -43.683 |
| Operating Margin | -292.634 |
| Pretax Margin | -345.808 |
| Net Margin | -345.358 |
| Return on Assets | -84.868 |
| Return on Equity | -100.884 |
| Return on Total Capital | -180.96 |
| Return on Invested Capital | -100.474 |
AMLX Capital Structure
| Total Debt to Total Equity | 1.202 |
| Total Debt to Total Capital | 1.188 |
| Total Debt to Total Assets | 1.023 |
| Long-Term Debt to Equity | 0.281 |
| Long-Term Debt to Total Capital | 0.278 |